MCID: LCL004
MIFTS: 35

Localized Osteosarcoma

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Localized Osteosarcoma

MalaCards integrated aliases for Localized Osteosarcoma:

Name: Localized Osteosarcoma 12 15 71
Localised Osteogenic Sarcoma 12
Localized Osteogenic Sarcoma 12
Localised Osteosarcoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3356
NCIt 49 C7780
UMLS 71 C0278511

Summaries for Localized Osteosarcoma

MalaCards based summary : Localized Osteosarcoma, also known as localised osteogenic sarcoma, is related to osteogenic sarcoma and middle ear carcinoma. An important gene associated with Localized Osteosarcoma is CSF3 (Colony Stimulating Factor 3), and among its related pathways/superpathways are Gastric cancer and Glioma. The drugs Peginterferon alfa-2b and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and liver.

Related Diseases for Localized Osteosarcoma

Diseases related to Localized Osteosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 osteogenic sarcoma 29.4 TP53 PARTICL IGF1R FRZB CDKN2A
2 middle ear carcinoma 10.3 EWSR1 CSF3
3 parotid gland adenoid cystic carcinoma 10.2 ERBB2 CDKN2A
4 fallopian tube endometrioid adenocarcinoma 10.1 ERBB2 CDKN2A
5 pleomorphic liposarcoma 10.1 EWSR1 CDKN2A
6 prostate squamous cell carcinoma 10.1 TP53 CDKN2A
7 vulvar intraepithelial neoplasia 10.0 TP53 CDKN2A
8 endometrial squamous cell carcinoma 10.0 TP53 CDKN2A
9 ovarian seromucinous carcinoma 10.0 TP53 CDKN2A
10 esophagus verrucous carcinoma 10.0 TP53 CDKN2A
11 spitz nevus 10.0 TP53 CDKN2A
12 bizarre leiomyoma 10.0 TP53 CDKN2A
13 squamous cell papilloma 10.0 TP53 CDKN2A
14 penile benign neoplasm 10.0 TP53 CDKN2A
15 suppressor of tumorigenicity 3 10.0 TP53 CDKN2A
16 tumor of exocrine pancreas 10.0 TP53 CDKN2A
17 oral leukoplakia 10.0 TP53 CDKN2A
18 thyroid lymphoma 10.0 TP53 CDKN2A
19 adult malignant schwannoma 10.0 TP53 CDKN2A
20 keratinizing squamous cell carcinoma 10.0 TP53 CDKN2A
21 adult astrocytic tumour 10.0 TP53 CDKN2A
22 bladder clear cell adenocarcinoma 10.0 TP53 CDKN2A
23 vulva squamous cell carcinoma 10.0 TP53 CDKN2A
24 bone squamous cell carcinoma 10.0 TP53 CDKN2A
25 low-grade astrocytoma 10.0 TP53 CDKN2A
26 familial retinoblastoma 10.0 TP53 CDKN2A
27 vaginal cancer 10.0 TP53 CDKN2A
28 periosteal osteogenic sarcoma 10.0 TP53 EWSR1
29 borst-jadassohn intraepidermal carcinoma 9.9 TP53 CDKN2A
30 sarcoma 9.9
31 spindle cell sarcoma 9.9
32 anal squamous cell carcinoma 9.9 TP53 CDKN2A
33 peripheral osteosarcoma 9.9 TP53 EWSR1
34 neurofibrosarcoma 9.9 TP53 CDKN2A
35 laryngeal benign neoplasm 9.9 TP53 CDKN2A
36 megaesophagus 9.9 TP53 CDKN2A
37 nodular malignant melanoma 9.9 TP53 CDKN2A
38 nasal cavity cancer 9.9 TP53 CDKN2A
39 pediatric osteosarcoma 9.9
40 inflammatory breast carcinoma 9.9 ERBB2 CSF3
41 childhood leukemia 9.8 TP53 CSF3 CDKN2A
42 uterus carcinoma in situ 9.8 TP53 CDKN2A
43 small cell cancer of the lung 9.8 TP53 CSF3 CDKN2A
44 cervix uteri carcinoma in situ 9.8 TP53 CDKN2A
45 peritoneum cancer 9.8 TP53 CDKN2A
46 soft tissue sarcoma 9.8 TP53 EWSR1 CSF3
47 anus cancer 9.8 TP53 CDKN2A
48 rhabdoid cancer 9.8 TP53 EWSR1 CDKN2A
49 gastric papillary adenocarcinoma 9.8 TP53 ERBB2
50 well-differentiated liposarcoma 9.8 TP53 EWSR1 CDKN2A

Graphical network of the top 20 diseases related to Localized Osteosarcoma:



Diseases related to Localized Osteosarcoma

Symptoms & Phenotypes for Localized Osteosarcoma

Drugs & Therapeutics for Localized Osteosarcoma

Drugs for Localized Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
2
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
9
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
10
Ifosfamide Approved Phase 3 3778-73-2 3690
11
leucovorin Approved Phase 3 58-05-9 6006 143
12
Zoledronic Acid Approved Phase 3 118072-93-8 68740
13
Histamine Approved, Investigational Phase 3 51-45-6 774
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
17 interferons Phase 3
18 Interferon-alpha Phase 3
19 Antiviral Agents Phase 3
20 Interferon alpha-2 Phase 3
21 Podophyllotoxin Phase 3 518-28-5
22 Keratolytic Agents Phase 3
23 Antidotes Phase 3
24 Cardiotonic Agents Phase 3
25 razoxane Phase 3
26 Protective Agents Phase 3
27 Antimitotic Agents Phase 3
28 Antitubercular Agents Phase 3
29 Antioxidants Phase 3
30 Chelating Agents Phase 3
31 Liver Extracts Phase 3
32 sodium thiosulfate Phase 3
33 Anesthetics Phase 3
34 Cola Phase 3
35 Analgesics Phase 3
36 Narcotics Phase 3
37 Analgesics, Opioid Phase 3
38 Anesthetics, General Phase 3
39 Anesthetics, Intravenous Phase 3
40 Etoposide phosphate Phase 3
41
Liposomal doxorubicin Phase 3 31703
42 Immunologic Factors Phase 3
43
Isophosphamide mustard Phase 3 0
44 Immunosuppressive Agents Phase 3
45 Alkylating Agents Phase 3
46 Vitamin B Complex Phase 3
47 Folate Phase 3
48 Folic Acid Antagonists Phase 3
49 Vitamin B9 Phase 3
50 Antibiotics, Antitubercular Phase 3

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy Unknown status NCT00134030 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
2 A RANDOMISED TRIAL OF CHEMOTHERAPY WITH OR WITHOUT GRANULOCYTE COLONY-STIMULATING FACTOR IN OPERABLE OSTEOSARCOMA Completed NCT00002539 Phase 3 cisplatin;doxorubicin hydrochloride
3 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
4 Protocol for Patients With Newly-Diagnosed Non-Metastatic Osteosarcoma - A POG/CCG Pilot Intergroup Study Completed NCT00003937 Phase 3 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate
5 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant Active, not recruiting NCT00470223 Phase 3 cisplatin;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate;zoledronic acid
7 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Phase II Study of Low-Dose Interferon Alfa 2B (Schering Plough) Plus Thalidomide (Celgene) for Patients With Resected High-Risk Soft Tissue Sarcoma Unknown status NCT00026416 Phase 2 thalidomide
9 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 High Dose Samarium-153 With Peripheral Blood Stem Cell Support in High Risk Osteogenic Sarcoma Completed NCT00245011 Phase 2 ifosfamide
11 Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response) Recruiting NCT03643133 Phase 2 Mifamurtide
12 Osteosarcoma: Outcome of Therapy Based on Histologic Response. A Collaborative Effort of the POB/NCI, Texas Children's Hospital and University of Oklahoma. Terminated NCT00019864 Phase 2 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;methotrexate
13 A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma Terminated NCT00880542 Phase 2 sorafenib;Ifosfamide
14 PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND IFOSFAMIDE, CARBOPLATIN AND TAXOL WITH AUTOLOGOUS STEM CELL SUPPORT Completed NCT00002854 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;mesna;paclitaxel
15 A Pilot Study of Irradiated HLA-Partially Matched Allogeneic Related Donor Lymphocytes for Patients With Selected Malignancies Completed NCT00161187 Phase 1
16 A Dose Finding Study of CycloSam® (153Sm-DOTMP) Combined With External Beam Radiotherapy to Treat High Risk Osteosarcoma and Other Solid Tumors Metastatic to Bone Not yet recruiting NCT03612466 Phase 1 153Sm-DOTMP;Calcium Carbonate;Mozobil;Neupogen Injectable Product
17 Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma Unknown status NCT01190943
18 Retrospective Study of Genetic Risk Factors for Osteosarcoma Completed NCT00954473
19 Localized Osteosarcoma of Extremities: Developing a Clinical Prediction Model From a Country With Limited Resources Completed NCT03839095
20 Observational - Methylation Status as Predictor of Response to Neoadjuvant Chemotherapy in Osteosarcoma Completed NCT01374672
21 Genomic Study of Metastatic Osteosarcoma Using Next-Generation Sequencing Technology Completed NCT01062438
22 Observational - Tissue Factor Expression in Bone Sarcomas Completed NCT01807052
23 Clinical and Biological Predictors of Therapy-Related Leukemia Completed NCT00003793
24 Glucose Metabolic Response by PET/CT to Sarcoma Treatments Completed NCT00335751
25 Treatment of Newly Diagnosed Untreated Osteosarcoma: A Pilot Study of a New Chemotherapeutic Regimen Including Ifosfamide Completed NCT00645632 cisplatin;doxorubicin hydrochloride;ifosfamide;methotrexate
26 A Retrospective Study of Extremity Osteosarcoma Patients Who Recieved Intra-arterial Limb Infusion of Cisplatin During Neoadjuvant Chemotherapy Completed NCT03909776 Cisplatin
27 A Randomized Study Of Electroacupuncture Treatment For Delayed Chemotherapy-Induced Nausea And Vomiting In Patients With Pediatric Solid Tumors Completed NCT00040911
28 Barriers to Patient Enrollment Onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proportion of Enrollment Completed NCT00002485
29 Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study Recruiting NCT03737435
30 Feasibility Study: Accuracy and Sensitivity of Deep-learning Artificial Intelligence (AI) Algorithm for Detection and Risk Stratification of Lung Nodules in Osteogenic Sarcoma Patients Recruiting NCT04022512
31 Prospective Observational Study of the Expression of ABCB1 / P-glycoprotein as a Factor for the Biological Stratification of Non-metastatic Osteosarcoma of the Extremities Recruiting NCT04383288
32 Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer Terminated NCT00499733 Early Phase 1 cyclophosphamide
33 Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study Withdrawn NCT00334984 glutamine
34 Prospective, Randomized Trial Comparing Heparin and Minocycline-EDTA Flush for the Prevention of Catheter-Related Infections and Occlusions Withdrawn NCT00378781 Heparin;Minocycline-EDTA

Search NIH Clinical Center for Localized Osteosarcoma

Genetic Tests for Localized Osteosarcoma

Anatomical Context for Localized Osteosarcoma

MalaCards organs/tissues related to Localized Osteosarcoma:

40
Bone, Lung, Liver, Brain, Kidney, Monocytes, T Cells

Publications for Localized Osteosarcoma

Articles related to Localized Osteosarcoma:

(show top 50) (show all 113)
# Title Authors PMID Year
1
CORR Insights®: Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma? 61
31977429 2020
2
Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma? 61
31904683 2020
3
Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma. 61
32475245 2020
4
CORR® Tumor Board: Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma? 61
32118597 2020
5
Maintenance therapy and drug holiday in sarcoma patients: systematic review. 61
32400254 2020
6
Engineering 2D Mesoporous Silica@MXene-Integrated 3D-Printing Scaffolds for Combinatory Osteosarcoma Therapy and NO-Augmented Bone Regeneration. 61
32108432 2020
7
Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt. 61
31107367 2020
8
Prognostic Factors for Development of Subsequent Metastases in Localized Osteosarcoma: A Systematic Review and Identification of Literature Gaps. 61
32300279 2020
9
Therapeutic Potential of Circular RNAs in Osteosarcoma. 61
32351876 2020
10
Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective. 61
32483726 2020
11
Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt. 61
30629005 2019
12
Can pretreatment 18F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy? 61
30859285 2019
13
Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma. 61
31024791 2019
14
Malignant Bone Tumors of the Knee: How to Identify and Treat. 61
30449025 2019
15
MiR-204-5p promotes apoptosis and inhibits migration of osteosarcoma via targeting EBF2. 61
30529043 2019
16
Lymphocyte-monocyte ratio at day 14 of first cisplatin-doxorubicin chemotherapy is associated with treatment outcome of pediatric patients with localized osteosarcoma. 61
30304898 2019
17
Treatment-Related Prognostic Factors in Managing Osteosarcoma around the Knee with Limb Salvage Surgery: A Lesson from a Long-Term Follow-Up Study. 61
31187043 2019
18
Crosstalk between Hh and Wnt signaling promotes osteosarcoma progression. 61
31933884 2019
19
The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment. 61
30193198 2018
20
Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources. 61
30241221 2018
21
Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. 61
29592877 2018
22
Current and future therapeutic approaches for osteosarcoma. 61
29210294 2018
23
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. 61
29340095 2017
24
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. 61
28631382 2017
25
Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma. 61
27918348 2017
26
p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases. 61
27544803 2016
27
Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. 61
27457945 2016
28
Risk-Based Therapy for Localized Osteosarcoma. 61
26501936 2016
29
Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. 61
26381138 2015
30
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. 61
26304877 2015
31
Prognostic value of pathologic fracture in patients with high grade localized osteosarcoma: a systemic review and meta-analysis of cohort studies. 61
25231396 2015
32
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. 61
26173023 2015
33
Letter to the editor: Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma. 61
25106799 2014
34
Reply to the Letter to the editor: Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma. 61
25099264 2014
35
Characterization of localized osteosarcoma of the extremity in children, adolescents, and young adults from a single institution in South Texas. 61
24487915 2014
36
Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma? 61
24719037 2014
37
Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. 61
24178953 2014
38
Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. 61
24924182 2014
39
Conditional survival is greater than overall survival at diagnosis in patients with osteosarcoma and Ewing's sarcoma. 61
23821136 2013
40
Pathologic fracture does not influence prognosis in stage IIB osteosarcoma: a case-control study. 61
23799947 2013
41
Current therapeutic strategies and novel approaches in osteosarcoma. 61
24216993 2013
42
Targeting hedgehog-GLI-2 pathway in osteosarcoma. 61
22968906 2013
43
Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma. 61
22972657 2013
44
New targets and approaches in osteosarcoma. 61
22983152 2013
45
Pathologic fracture does not influence local recurrence and survival in high-grade extremity osteosarcoma with adequate surgical margins. 61
22740310 2012
46
Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. 61
22648705 2012
47
Meta-analysis of limb salvage versus amputation for treating high-grade and localized osteosarcoma in patients with pathological fracture. 61
23226744 2012
48
Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). 61
22415578 2012
49
Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma. 61
22854993 2012
50
[Results of the treatment of pediatric osteosarcoma in the Hungarian population]. 61
22403760 2012

Variations for Localized Osteosarcoma

Expression for Localized Osteosarcoma

Search GEO for disease gene expression data for Localized Osteosarcoma.

Pathways for Localized Osteosarcoma

GO Terms for Localized Osteosarcoma

Biological processes related to Localized Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.43 IGF1R ERBB2 CSF3
2 negative regulation of cell growth GO:0030308 9.33 TP53 FRZB CDKN2A
3 replicative senescence GO:0090399 8.96 TP53 CDKN2A
4 negative regulation of immature T cell proliferation in thymus GO:0033088 8.62 ERBB2 CDKN2A

Sources for Localized Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....